AML08: A Phase III Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia.

Trial Profile

AML08: A Phase III Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Clofarabine (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Diphenhydramine; Doxorubicin; Etoposide; Fludarabine; Folinic acid; Folinic acid; Gemtuzumab ozogamicin; Hydrocortisone; Hydrocortisone; Interleukin-2; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methylprednisolone; Mitoxantrone; Prednisone; Sorafenib; Tioguanine; Valproic acid; Vincristine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Apr 2017 Planned End Date changed from 1 Aug 2019 to 30 Jun 2020.
    • 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top